L Mahady1,2, M Nadeem1, M Malek-Ahmadi3, K Chen3, S E Perez1, E J Mufson1. 1. Department of Neurobiology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. 2. Arizona State University Interdisciplinary Graduate Program in Neuroscience, Tempe, Arizona, USA. 3. Banner Alzheimer's Institute, Phoenix, Arizona, USA.
Abstract
AIMS: Alzheimer's disease (AD) is characterized by degeneration of cholinergic basal forebrain (CBF) neurons in the nucleus basalis of Meynert (nbM), which provides the major cholinergic input to the cortical mantle and is related to cognitive decline in patients with AD. Cortical histone deacetylase (HDAC) dysregulation has been associated with neuronal degeneration during AD progression. However, whether HDAC alterations play a role in CBF degeneration during AD onset is unknown. We investigated global HDAC protein levels and nuclear HDAC2 immunoreactivity in tissue containing the nbM, changes and their association with neurofibrillary tangles (NFTs) during the progression of AD. METHODS: We used semi-quantitative western blotting and immunohistochemistry to evaluate HDAC and sirtuin (SIRT) levels in individuals that died with a premortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD) or severe AD (sAD). Quantitative immunohistochemistry was used to identify HDAC2 protein levels in individual cholinergic nbM nuclei and their colocalization with the early phosphorylated tau marker AT8, the late-stage apoptotic tau marker TauC3 and Thioflavin-S, a marker of β-pleated sheet structures in NFTs. RESULTS: In AD patients, HDAC2 protein levels were dysregulated in the basal forebrain region containing cholinergic neurons of the nbM. HDAC2 nuclear immunoreactivity was reduced in individual cholinergic nbM neurons across disease stages. HDAC2 nuclear reactivity correlated with multiple cognitive domains and with NFT formation. CONCLUSIONS: These findings suggest that HDAC2 dysregulation contributes to cholinergic nbM neuronal dysfunction, NFT pathology, and cognitive decline during clinical progression of AD.
AIMS: Alzheimer's disease (AD) is characterized by degeneration of cholinergic basal forebrain (CBF) neurons in the nucleus basalis of Meynert (nbM), which provides the major cholinergic input to the cortical mantle and is related to cognitive decline in patients with AD. Cortical histone deacetylase (HDAC) dysregulation has been associated with neuronal degeneration during AD progression. However, whether HDAC alterations play a role in CBF degeneration during AD onset is unknown. We investigated global HDAC protein levels and nuclear HDAC2 immunoreactivity in tissue containing the nbM, changes and their association with neurofibrillary tangles (NFTs) during the progression of AD. METHODS: We used semi-quantitative western blotting and immunohistochemistry to evaluate HDAC and sirtuin (SIRT) levels in individuals that died with a premortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD) or severe AD (sAD). Quantitative immunohistochemistry was used to identify HDAC2 protein levels in individual cholinergic nbM nuclei and their colocalization with the early phosphorylated tau marker AT8, the late-stage apoptotic tau marker TauC3 and Thioflavin-S, a marker of β-pleated sheet structures in NFTs. RESULTS: In ADpatients, HDAC2 protein levels were dysregulated in the basal forebrain region containing cholinergic neurons of the nbM. HDAC2 nuclear immunoreactivity was reduced in individual cholinergic nbM neurons across disease stages. HDAC2 nuclear reactivity correlated with multiple cognitive domains and with NFT formation. CONCLUSIONS: These findings suggest that HDAC2 dysregulation contributes to cholinergic nbM neuronal dysfunction, NFT pathology, and cognitive decline during clinical progression of AD.
Authors: Elliott J Mufson; Shuang Y Ma; John Dills; Elizabeth J Cochran; Sue Leurgans; Joanne Wuu; David A Bennett; Syed Jaffar; Michelle L Gilmor; Alan I Levey; Jeffrey H Kordower Journal: J Comp Neurol Date: 2002-02-04 Impact factor: 3.215
Authors: E J Mufson; S Y Ma; E J Cochran; D A Bennett; L A Beckett; S Jaffar; H U Saragovi; J H Kordower Journal: J Comp Neurol Date: 2000-11-06 Impact factor: 3.215
Authors: Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: Robert S Wilson; Laurel A Beckett; Lisa L Barnes; Julie A Schneider; Julie Bach; Denis A Evans; David A Bennett Journal: Psychol Aging Date: 2002-06
Authors: Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson Journal: Acta Neuropathol Date: 2019-02-07 Impact factor: 17.088
Authors: Jose A Gomez-Sanchez; Nikiben Patel; Fernanda Martirena; Shaline V Fazal; Clara Mutschler; Hugo Cabedo Journal: Int J Mol Sci Date: 2022-03-10 Impact factor: 5.923
Authors: Harald Frankowski; Fred Yeboah; Bonnie J Berry; Chizuru Kinoshita; Michelle Lee; Kira Evitts; Joshua Davis; Yoshito Kinoshita; Richard S Morrison; Jessica E Young Journal: Int J Mol Sci Date: 2021-03-03 Impact factor: 5.923